Kenneth Ouriel MD, MBA

Kenneth Ouriel, MD, MBA currently serves as Chief Medical Officer of NAMSA. With a dedication to exploring and advancing less invasive medical procedures to treat diseases, Dr. Ouriel has become a renowned Vascular Surgeon throughout his career. Dr. Ouriel’s exceptional career has made him a highly respected figure in the medical and business communities. He is committed to developing innovative medical techniques and advancing the field of medicine through research and collaboration, inspiring many in the industry.

Dr. Ouriel began his professional journey as a practicing Vascular Surgeon at the University of Rochester, where he completed his residency in General Surgery and Fellowship in Vascular Surgery. He then moved on to become the Chief of Vascular Surgery at the Cleveland Clinic, where he was promoted to the Chief of Surgery in 2003. He also oversaw the Cleveland Clinic’s Abu Dhabi facility before joining the New York Presbyterian Hospital as Chief of International Operations.

In 2010, Dr. Ouriel founded Syntactx, a Clinical Research Organization (CRO) that focused on Cardiovascular medical device trials. Syntactx was acquired by NAMSA in December 2020, with Dr. Ouriel assuming the role of Chief Medical Officer.

Dr. Ouriel has published over 325 scientific articles and authored five textbooks, demonstrating his extensive contributions to the field of medicine. He has served on several industry association boards, including the Society for Vascular Surgery, the Society for Clinical Trials, and the Vascular and Endovascular Surgery Society.

With an interest in the business aspects of medicine, Dr. Ouriel pursued an MBA from Columbia University and the London Business School.